DaVita Inc. (DVA) Stock Price & Analysis
DaVita Inc. (DVA) closed at USD 186.1 on Thursday, October 22, 2026, up 5.25% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 176.81; the Oct 22, 2026 session ranged USD 176.38–186.91 on volume of 930,808 shares. Market capitalization is $11.87B, with a 52-week range of USD 101–247.49 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DVA.md
Key facts (DVA)
- Last four reported quarters (through Jun 30, 2026): revenue $14.0B, net income $847M (6.0% margin), free cash flow $1.61B (SEC filings).
- Valuation: P/E 14.0x (avg 13.2x at the last 3 fiscal year-ends), EV/EBITDA 7.8x, net debt $10.1B.
- 1 of 80 tracked superinvestors hold DVA (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $254M; 6 not under a Rule 10b5-1 plan ($251M); 2 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.88 on a 1–5 scale) (8 analysts), mean target USD 219.86 (range 165–270).
- Total return with dividends: 1Y +45.4% vs S&P 500 +14.9%; 5Y +61.0% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 3.57, revenue estimate $3.52B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DVA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B | $14.0B |
| Operating income | $1.80B | $1.34B | $1.60B | $2.09B | $2.04B | $2.13B |
| Net income | $978M | $560M | $692M | $936M | $747M | $847M |
| EPS (diluted) | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 | — |
| Free cash flow | $1.29B | $961M | $1.49B | $1.47B | $1.31B | $1.61B |
| Operating margin | 15.5% | 11.5% | 13.2% | 16.3% | 15.0% | 15.2% |
| Net margin | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% | 6.0% |
| Revenue growth | +0.6% | -0.1% | +4.6% | +5.6% | +6.5% | — |
| Cash + short-term investments | $484M | $322M | $392M | $846M | $701M | — |
| Total debt | $8.91B | $8.92B | $8.39B | $9.45B | $10.3B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DVA)
P/E 14.0x · P/S 0.8x · EV/EBITDA 7.8x · EV/Sales 1.6x · P/FCF 7.4x · FCF yield 13.56% · Earnings yield 7.14% · Buyback yield (TTM) 7.52% · Net debt $10.1B · EV $22.0B
P/E at fiscal year-ends: Dec 2025 11.5x, Dec 2024 13.9x, Dec 2023 14.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (DVA)
1 of 80 tracked investors hold DVA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Warren Buffett | Berkshire Hathaway | 2.15% | $6.43B | Reduced -4.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (DVA)
2 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Berkshire Hathaway Inc | 182,980 | $36.5M | 0.6% | No | Too little history (no open-market trades in 2023 or 2024) | |
| 2026-06-15…2026-06-16 | Rodriguez Javier | Chief Executive Officer | 69,407 | $14.5M | 7.6% | No | Too little history (no open-market trades in 2025) |
| 2026-06-15 | Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off | 15,405 | $3.2M | 12.4% | Yes (adopted March 16, 2026) | Too little history (no open-market trades in 2025) |
| 2026-05-15 | Hearty James O | Chief Compliance Officer | 15,000 | $2.9M | 40.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-11…2026-05-12 | Maughan David Paul | Chief Operating Officer, DKC | 20,529 | $4.1M | 17.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-07 | Ackerman Joel | CFO and Treasurer | 51,471 | $9.9M | 28% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-06 | Hearty James O | Chief Compliance Officer | 2,184 | $382K | 5.7% | Yes (adopted December 15, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-01 | Berkshire Hathaway Inc | 1,220,376 | $183M | 4.1% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DVA)
Consensus Hold (mean 2.88 on a 1–5 scale), 8 analysts; mean target USD 219.86 (low 165, high 270).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | TD Cowen | Upgrade | Hold → Buy | $201 → $220 |
| 2026-08-07 | Truist Securities | Target lowered | Hold | $250 → $215 |
| 2026-08-05 | Barclays | Target raised | Equal-Weight | $218 → $224 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $205 → $250 |
| 2026-07-10 | UBS | Target raised | Buy | $235 → $270 |
| 2026-07-09 | Barclays | Target raised | Equal-Weight | $194 → $218 |
Total return (dividends reinvested) (DVA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +45.4% | +61.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +45.5% | +10.0% |
| Volatility (annualized) | 45.3% | 37.9% |
| Max drawdown | -27.9% (Jul 2026→Aug 2026) | -42.3% (Apr 2022→Oct 2022) |
DVA revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U S Dialysis And Related Lab Services with Intersegment | $3.01B | 84.7% | +3.4% |
| U. S. Dialysis And Related Lab Services | $3.00B | 84.4% | +3.6% |
| Other Operating Segments with Intersegment | $556.7M | 15.7% | +14.6% |
| Other - Ancillary Services | $553.6M | 15.6% | +14.7% |
| Total revenue | $3.55B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DVA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | BERKSHIRE HATHAWAY INC (BRK-B) | “See further discussion of our share repurchase activity, authorizations and information on our share repurchase agreement with Berkshire in Note 18 to the consolidated financial statements.” |
Quoted from the company's 10-K filed Feb 11, 2026.
Companies that name DVA in their SEC reports
| Relationship to DVA | Company | Filing | Sentence |
|---|---|---|---|
| customer | ROCKWELL MEDICAL, INC. (RMTI) | 10-K Mar 26, 2026 | “•In December 2025, we amended our Amended and Restated Product Purchase Agreement (the "Amended Agreement") dated September 18, 2023 with DaVita, Inc. ("DaVita"), extending the term through December 31, 2026.” |
| supplier | Akebia Therapeutics, Inc. (AKBA) | 10-K Feb 26, 2026 | “Three dialysis organizations, DaVita, Fresenius Medical Care Rx and USRC, in the aggregate, accounted for a significant percentage of our gross revenue from Auryxia and Vafseo during the year ended December 31, 2025.” |
| partner | Outset Medical, Inc. (OM) | 10-K Feb 13, 2026 | “Currently, the provision of in-clinic and home dialysis is largely dominated by DaVita and Fresenius, and our expansion within the home dialysis market is dependent on our ability to grow new home programs with health systems and innovative dialysis clinic partners.” |
| partner | Marti Technologies, Inc. (MRT) | 10-K Mar 31, 2023 | “Prior to founding Cedar Investors, Tim was an operator at DaVita Inc. (NYSE: DVA) where he focused on initiatives including strategic partnerships with health insurance companies.” |
DVA company outlook (results filed Aug 4, 2026)
- “The guidance for our effective income tax rate on adjusted income attributable to DaVita Inc. also excludes the amount of third-party owners' income and related taxes attributable to non-tax paying entities.”
- “Current 2026 guidance Low High (dollars in millions, except per share data) Adjusted operating income $2,150 $2,250 Adjusted diluted net income per share attributable to DaVita Inc. $14.10 $15.20 Free cash flow $1,000 $1,250 The following table outlines normalized treatment days by quarter for 2025 and 2026.”
Quoted word-for-word from the SEC 8-K results press release.
DVA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.57 | $3.93 | -9.1% | $3.52B | 7 |
| Next quarter (ends Dec 2026) | $4.40 | $4.24 | +3.7% | $3.61B | 7 |
| Current fiscal year (ends Dec 2026) | $14.82 | $14.88 | -0.4% | $14.16B | 7 |
| Next fiscal year (ends Dec 2027) | $17.14 | $17.22 | -0.5% | $14.64B | 8 |
DVA options: expected move
Options price a move of about ±12.1% (±$22.70) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±13% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 53.3% | ±12.1% |
| Dec 18, 2026 | 56 | 43.6% | ±13.8% |
| Jan 15, 2027 | 84 | 40.4% | ±15.5% |
| Feb 19, 2027 | 119 | 42.7% | ±19.5% |
| Apr 16, 2027 | 175 | 40.4% | ±22.2% |
| May 21, 2027 | 210 | 42.0% | ±25.3% |
| Aug 20, 2027 | 301 | 41.0% | ±29.4% |
| Nov 19, 2027 | 392 | 40.7% | ±33.1% |
30-day implied volatility 51.2% vs 40.2% realized over the last 30 trading days. Put/call ratio (volume) 0.27. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 186.1 |
|---|---|
| Change | ▲ 5.25% (up) |
| Previous Close | USD 176.81 |
| Open | USD 176.89 |
| Day Range | USD 176.38 – 186.91 |
| 52-Week Range | USD 101 – 247.49 |
| Volume | 930,808 shares |
| Market Cap | $11.87B |
| Exchange | NYQ |
Technical Analysis (DVA)
Nexqual's technical model rates DVA "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.98 (neutral) |
| vs SMA50 | Above (USD 180.45) |
| MACD | -0.1 (negative) |
Analyst Ratings (DVA)
Wall Street analysts rate DVA "Hold" based on 8 analysts, with a mean price target of USD 219.86 (range USD 165–270), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 219.86 |
| High Target | USD 270 |
| Low Target | USD 165 |
| Buy / Hold / Sell | 3 / 4 / 1 |
Earnings (DVA)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 3.57 |
| Revenue Estimate | $3.52B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.02 vs est 3.88 ▲ beat |
| 2026-03-31 | USD 2.87 vs est 2.33 ▲ beat |
| 2025-12-31 | USD 3.4 vs est 3.19 ▲ beat |
| 2025-09-30 | USD 2.51 vs est 3.17 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (DVA)
| Total Revenue | $14.01B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.20% |
| Gross Margin | +32.36% |
| Operating Margin | +16.06% |
| Profit Margin | +6.05% |
| ROE | +88.48% |
| Debt / Equity | 12.42 |
| Current Ratio | 1.47 |
| Total Cash | $688.88M |
| Total Debt | $13.41B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.61B (11.5% of revenue) |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (DVA)
Nexqual rates DaVita Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 16% (last 12 months) |
| Balance Sheet | Critical — $689M cash and investments vs $10.8B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $1.61B (last 4 quarters to Jun 2026, SEC), 11% margin |
| Efficiency | Strong — ROE 88%, ROA 7.5% |
Ownership (DVA)
| Insider Ownership | +46.91% |
|---|---|
| Institutional Ownership | +48.47% |
| Shares Outstanding | 63.80M |
| Float | 33.93M |
| Short % of Float | +15.87% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (DVA)
DaVita Inc. is led by Javier J. Rodriguez, CEO & Executive Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| CEO & Executive Director | Javier J. Rodriguez |
|---|---|
| CFO & Treasurer | Joel Ackerman |
| Chief Operating Officer of DaVita Kidney Care | David P. Maughan |
| Group Vice President of Investor Relations | Nic Eliason |
Major Backers & Investors (DVA)
Notable institutional backers of DaVita Inc. include Berkshire Hathaway, Morgan Stanley, Invesco, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Berkshire Hathaway | 45.27% |
| Morgan Stanley | 2.51% |
| Invesco | 1.9% |
| Neuberger Berman Group, LLC | 1.45% |
| LSV Asset Management | 1.42% |
| Fidelity | 0.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.45% |
| BlackRock | 3.86% |
| State Street | 2.07% |
| Dimensional Fund Advisors | 1.78% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From DaVita Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care.
- We have made and continue to make investments in building our integrated care capabilities, including the operation of certain strategic business initiatives that are intended to integrate and coordinate care among healthcare participants across the renal care continuum from CKD to ESKD to kidney transplant.
Partnerships
- The sources of our U.S. dialysis revenues are principally from government-based programs, including Medicare and Medicare Advantage plans, Medicaid and managed Medicaid plans, other government-based programs including our agreement with the Veterans Administration, and commercial insurance plans.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements or in federal or state legislation or regulations, could have a material adverse effect on our business, and operations, and in some circumstances, could materially harm our reputation.
- We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters, which could have a material adverse effect on our business, results of operations, financial condition, cash flows and stock price and could materially harm our reputation.
- Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or medical equipment or supplies could have a material adverse effect on our business, results of operations, financial condition, and cash flows and materially harm our reputation.
- Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personally identifiable information on our behalf, it could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt